End-of-day quote
Shanghai S.E.
06:00:00 2024-06-16 pm EDT
|
5-day change
|
1st Jan Change
|
61.8
CNY
|
+1.69%
|
|
-0.93%
|
-5.29%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,895
|
11,989
|
7,551
|
9,916
|
9,392
|
-
|
-
|
Enterprise Value (EV)
1 |
3,895
|
11,989
|
7,551
|
9,916
|
9,392
|
9,392
|
9,392
|
P/E ratio
|
26.4
x
|
37
x
|
18.5
x
|
19.1
x
|
15.3
x
|
12.3
x
|
10.2
x
|
Yield
|
-
|
-
|
-
|
1.84%
|
2.52%
|
3.09%
|
-
|
Capitalization / Revenue
|
-
|
3.66
x
|
2.07
x
|
2.35
x
|
1.9
x
|
1.65
x
|
1.45
x
|
EV / Revenue
|
-
|
3.66
x
|
2.07
x
|
2.35
x
|
1.9
x
|
1.65
x
|
1.45
x
|
EV / EBITDA
|
-
|
29.7
x
|
15.4
x
|
15.9
x
|
13.1
x
|
11.9
x
|
8.93
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
7.75
x
|
4.09
x
|
4.45
x
|
3.39
x
|
2.8
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
153,399
|
151,967
|
151,967
|
151,967
|
151,967
|
-
|
-
|
Reference price
2 |
25.39
|
78.89
|
49.69
|
65.25
|
61.80
|
61.80
|
61.80
|
Announcement Date
|
3/15/21
|
3/17/22
|
3/14/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,278
|
3,641
|
4,213
|
4,931
|
5,680
|
6,478
|
EBITDA
1 |
-
|
403.2
|
490.2
|
625.6
|
719
|
790.9
|
1,052
|
EBIT
1 |
-
|
365.2
|
442.2
|
573.9
|
685.9
|
844.3
|
1,025
|
Operating Margin
|
-
|
11.14%
|
12.14%
|
13.62%
|
13.91%
|
14.87%
|
15.82%
|
Earnings before Tax (EBT)
1 |
-
|
360.9
|
437.9
|
571.1
|
682
|
840.8
|
1,021
|
Net income
1 |
147.8
|
324.7
|
407.6
|
521.5
|
619.2
|
768.2
|
927.4
|
Net margin
|
-
|
9.91%
|
11.19%
|
12.38%
|
12.56%
|
13.52%
|
14.32%
|
EPS
2 |
0.9600
|
2.130
|
2.680
|
3.410
|
4.035
|
5.007
|
6.045
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
1.200
|
1.560
|
1.910
|
-
|
Announcement Date
|
3/15/21
|
3/17/22
|
3/14/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
22.6%
|
25.3%
|
25.5%
|
22.1%
|
22.7%
|
21.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
12.5%
|
12.9%
|
14.1%
|
13.9%
|
Assets
1 |
-
|
-
|
-
|
4,168
|
4,800
|
5,450
|
6,672
|
Book Value Per Share
2 |
-
|
10.20
|
12.10
|
14.70
|
18.20
|
22.10
|
28.30
|
Cash Flow per Share
2 |
-
|
1.700
|
1.410
|
1.750
|
2.300
|
2.910
|
4.510
|
Capex
1 |
-
|
-
|
-
|
61.6
|
30
|
42.5
|
30
|
Capex / Sales
|
-
|
-
|
-
|
1.46%
|
0.61%
|
0.75%
|
0.46%
|
Announcement Date
|
3/15/21
|
3/17/22
|
3/14/23
|
3/15/24
|
-
|
-
|
-
|
Last Close Price
61.8
CNY Average target price
87.74
CNY Spread / Average Target +41.97% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.29% | 1.27B | | +51.82% | 791B | | +40.45% | 630B | | +16.95% | 328B | | +9.49% | 298B | | +17.25% | 246B | | +0.41% | 225B | | +10.22% | 218B | | +5.30% | 160B | | -6.29% | 156B |
Other Pharmaceuticals
|